{"product_id":"the-ada-practical-guide-to-substance-use-disorders-and-safe-prescribing-9781118886014","title":"The ADA Practical Guide to Substance Use Disorders and Safe Prescribing","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eDentists have been inundated by patients with an array of complicated medical conditions and pain\/sedation management issues. This is in addition to a variety of legal regulations dentists must follow regarding the storage and recordkeeping of controlled substances. Avoid unknowingly putting your practice at risk by becoming victim to a scam or violating a recordkeeping requirement with The \u003ci\u003eADA Practical Guide to Substance Use Disorders and Safe Prescribing\u003c\/i\u003e.\u003c\/p\u003e \u003cp\u003eThis \u003ci\u003ePractical Guide\u003c\/i\u003e is ideal for dentists and staff as they navigate:\u003c\/p\u003e \u003cp\u003eDetecting and deterring substance use disorders (SUD) and drug diversion in the dental office (drug-seeking patients)\u003cbr\u003e Prescribing complexities\u003cbr\u003e Treating patients with SUD and complex analgesic and sedation (pain\/sedation management) needs and the best use of sedation anxiety medication\u003cbr\u003e Interviewing and counselling options for SUD\u003cbr\u003e Federal drug regulations\u003cbr\u003e Commonly used illicit, prescription, and over-the\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eContributors xi\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003eAcknowledgments xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Substance Use Disorders, Drug Diversion, and Pain Management: The Scope of the Problem 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003eDefinitions 2\u003c\/p\u003e \u003cp\u003eSubstance Use Disorder, Drug Misuse, Drug Diversion, and Pain Management in the Dental Community 4\u003c\/p\u003e \u003cp\u003eUnderstanding the Cultures of Substance Use Disorder, Drug Misuse, and Drug Diversion 8\u003c\/p\u003e \u003cp\u003eSummary 9\u003c\/p\u003e \u003cp\u003eReferences 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Understanding the Disease of Substance Use Disorders 11\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJames H. Berry, DO and Carl Rollynn Sullivan, MD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 11\u003c\/p\u003e \u003cp\u003eDefinitions 11\u003c\/p\u003e \u003cp\u003eEpidemiology: Drug\/Alcohol 13\u003c\/p\u003e \u003cp\u003ePathophysiology\/Brain Pathways 14\u003c\/p\u003e \u003cp\u003eSigns, Symptoms, Behavior 15\u003c\/p\u003e \u003cp\u003eTreatment Methods 20\u003c\/p\u003e \u003cp\u003eSummary 26\u003c\/p\u003e \u003cp\u003eAppendix 2.A: Common Opioid Analgesics and their Brand Names 27\u003c\/p\u003e \u003cp\u003eReferences 29\u003c\/p\u003e \u003cp\u003eResources and Further Readings 30\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Principles of Pain Management in Dentistry 31\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePaul A. Moore, DMD, PhD, MPH and Elliot V. Hersh, DMD, MS, PhD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 31\u003c\/p\u003e \u003cp\u003eDefinitions 32\u003c\/p\u003e \u003cp\u003eNeurophysiology and Neuroanatomy of Acute Inflammatory Pain 32\u003c\/p\u003e \u003cp\u003eOrally Administered Analgesic Agents 33\u003c\/p\u003e \u003cp\u003eMedication-Assisted Therapies for Treating Drug-Dependent Patients 41\u003c\/p\u003e \u003cp\u003eAdjunctive Drugs Used to Limit Pain in Dentistry 41\u003c\/p\u003e \u003cp\u003eGuidelines for Analgesic Therapy 43\u003c\/p\u003e \u003cp\u003eSummary 45\u003c\/p\u003e \u003cp\u003eReferences 45\u003c\/p\u003e \u003cp\u003eResources and Further Readings 46\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Special Pain Management Considerations: (1) Chronic Methadone, Buprenorphine, and Naltrexone Therapy; (2) Chronic Opioids for Nonmalignant Pain 47\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 47\u003c\/p\u003e \u003cp\u003eDefinitions 48\u003c\/p\u003e \u003cp\u003eInterviewing the Patient: Establishing Goals of Treatment 49\u003c\/p\u003e \u003cp\u003ePharmacological Treatment of Opioid Addiction 49\u003c\/p\u003e \u003cp\u003eTreating Acute Dental Pain 51\u003c\/p\u003e \u003cp\u003eAcute Pain in Patients Receiving Opioid Maintenance Therapy 51\u003c\/p\u003e \u003cp\u003eThe Active Opioid Addict 55\u003c\/p\u003e \u003cp\u003eAcute Pain Management in Patients Receiving Naltrexone Therapy 56\u003c\/p\u003e \u003cp\u003eAcute Pain Management in Patients Receiving Opioids for Chronic Pain 57\u003c\/p\u003e \u003cp\u003eSummary 57\u003c\/p\u003e \u003cp\u003eReferences 58\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Sedation and Anxiolysis 61\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMatthew Cooke, DDS, MD, MPH\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 61\u003c\/p\u003e \u003cp\u003eDefinitions 61\u003c\/p\u003e \u003cp\u003eSpectrum of Anesthesia and Sedation 62\u003c\/p\u003e \u003cp\u003ePreoperative Evaluation 64\u003c\/p\u003e \u003cp\u003ePhysical Status Classification 65\u003c\/p\u003e \u003cp\u003eSedation 65\u003c\/p\u003e \u003cp\u003eMedications Available for Sedation of Patients with Substance Use Disorder 68\u003c\/p\u003e \u003cp\u003eThe Concept of Balanced Anesthesia 76\u003c\/p\u003e \u003cp\u003eMonitoring and Documentation 76\u003c\/p\u003e \u003cp\u003eSummary 78\u003c\/p\u003e \u003cp\u003eDisclaimer 78\u003c\/p\u003e \u003cp\u003eReferences 79\u003c\/p\u003e \u003cp\u003eResources and Further Readings 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Common Substances and Medications of Abuse 83\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWilliam J. Maloney, DDS and George F. Raymond, DDS\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 83\u003c\/p\u003e \u003cp\u003eDefinitions 83\u003c\/p\u003e \u003cp\u003eSigns and Symptoms of Substance Use Disorder 85\u003c\/p\u003e \u003cp\u003eCommon Substances of Abuse 86\u003c\/p\u003e \u003cp\u003ePrescription Medications 100\u003c\/p\u003e \u003cp\u003eOver-the-Counter Medications 111\u003c\/p\u003e \u003cp\u003eSummary 112\u003c\/p\u003e \u003cp\u003eReferences 112\u003c\/p\u003e \u003cp\u003eResources and Further Readings 118\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Tobacco Cessation: Behavioral and Pharmacological Considerations 119\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eFrank Vitale, MA and Amanda Eades, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 119\u003c\/p\u003e \u003cp\u003eDefinitions 119\u003c\/p\u003e \u003cp\u003eForms of Tobacco 121\u003c\/p\u003e \u003cp\u003eOral Effects of Tobacco Use 121\u003c\/p\u003e \u003cp\u003eDental Practitioner Management of Tobacco Use 122\u003c\/p\u003e \u003cp\u003eSpit Tobacco Interventions 124\u003c\/p\u003e \u003cp\u003eOral Substitutes 125\u003c\/p\u003e \u003cp\u003eSocial Support\/Disapproval 125\u003c\/p\u003e \u003cp\u003eMedication Management for Smoking Cessation 126\u003c\/p\u003e \u003cp\u003eThe Role of Nicotine 126\u003c\/p\u003e \u003cp\u003ePharmacotherapy Options 127\u003c\/p\u003e \u003cp\u003eSummary 138\u003c\/p\u003e \u003cp\u003eReferences 138\u003c\/p\u003e \u003cp\u003eResources and Further Readings 140\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Detection and Deterrence of Substance Use Disorders and Drug Diversion in Dental Practice 141\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSarah T. Melton, PharmD, BCPP, BCACP, CGP, FASCP and Ralph A. Orr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 141\u003c\/p\u003e \u003cp\u003eDefinitions 141\u003c\/p\u003e \u003cp\u003eScreening Patients for Substance Use Disorder 142\u003c\/p\u003e \u003cp\u003eSchemes and Scams to Obtain Prescription Drugs 144\u003c\/p\u003e \u003cp\u003eDental Practitioner- and Office Personnel-Related Prescription Drug Diversion 147\u003c\/p\u003e \u003cp\u003ePrescription Drug Monitoring Programs 148\u003c\/p\u003e \u003cp\u003eDisposal of Controlled Substances 153\u003c\/p\u003e \u003cp\u003eUniversal Precautions in Prescribing Controlled Substances 154\u003c\/p\u003e \u003cp\u003eSummary 157\u003c\/p\u003e \u003cp\u003eReferences 157\u003c\/p\u003e \u003cp\u003eResources and Further Readings 158\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Interviewing and Counseling Patients with Known or Suspected Substance Use Disorders: Dealing with Drug-seeking Patients 159\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGeorge F. Raymond, DDS and William J. Maloney, DDS\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 159\u003c\/p\u003e \u003cp\u003eDefinitions 160\u003c\/p\u003e \u003cp\u003ePreinterview Considerations 160\u003c\/p\u003e \u003cp\u003ePatient Interview Considerations 161\u003c\/p\u003e \u003cp\u003eInterviewing and Counseling Techniques 162\u003c\/p\u003e \u003cp\u003eWhat Questions Should Be Asked? 163\u003c\/p\u003e \u003cp\u003eScreening Tools 164\u003c\/p\u003e \u003cp\u003eDocumentation 165\u003c\/p\u003e \u003cp\u003eSummary 166\u003c\/p\u003e \u003cp\u003eReferences 166\u003c\/p\u003e \u003cp\u003eResources and Further Readings 167\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Office Management of Controlled Substances 169\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eCarlos M. Aquino\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 169\u003c\/p\u003e \u003cp\u003eFederal Statutes and Regulations 169\u003c\/p\u003e \u003cp\u003eDefinitions 169\u003c\/p\u003e \u003cp\u003eCommon Violations by Dental Practitioners 170\u003c\/p\u003e \u003cp\u003eSurviving a Drug Enforcement Administration Inspection 173\u003c\/p\u003e \u003cp\u003ePractice Due Diligence Program 175\u003c\/p\u003e \u003cp\u003eManagement of Noncontrolled Substances in the Office 176\u003c\/p\u003e \u003cp\u003eSummary 176\u003c\/p\u003e \u003cp\u003eResources and Further Readings 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Addiction and Impairment in the Dental Professional 177\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWilliam T. Kane, DDS, MBA, FAGD, FACD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 177\u003c\/p\u003e \u003cp\u003eDefinitions 178\u003c\/p\u003e \u003cp\u003eThe Complexity of Addiction 178\u003c\/p\u003e \u003cp\u003eThe Neurobiology of Addiction 179\u003c\/p\u003e \u003cp\u003eThe Stigma of Addiction 180\u003c\/p\u003e \u003cp\u003eEpidemiology of Addiction in Dentistry 180\u003c\/p\u003e \u003cp\u003eRisk Factors for Substance Use Disorder 180\u003c\/p\u003e \u003cp\u003eSubstances of Choice 182\u003c\/p\u003e \u003cp\u003eIdentifying Addiction 183\u003c\/p\u003e \u003cp\u003e“The Conspiracy of Silence” 183\u003c\/p\u003e \u003cp\u003eIntervention 184\u003c\/p\u003e \u003cp\u003eEvaluation\/Assessment 185\u003c\/p\u003e \u003cp\u003eTreatment 186\u003c\/p\u003e \u003cp\u003eFamily and Staff 186\u003c\/p\u003e \u003cp\u003eRelapse 187\u003c\/p\u003e \u003cp\u003eMonitoring 187\u003c\/p\u003e \u003cp\u003ePeer Assistance or Dental Well-being Committee Programs 187\u003c\/p\u003e \u003cp\u003eSummary 189\u003c\/p\u003e \u003cp\u003eReferences 189\u003c\/p\u003e \u003cp\u003eResources and Further Readings 190\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Due Diligence and Safe Prescribing 191\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMichael O’Neil, PharmD\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 191\u003c\/p\u003e \u003cp\u003eDefinitions 191\u003c\/p\u003e \u003cp\u003eCase Scenarios 192\u003c\/p\u003e \u003cp\u003eSummary 205\u003c\/p\u003e \u003cp\u003eReferences 206\u003c\/p\u003e \u003cp\u003eContinuing Education Examination 207\u003c\/p\u003e \u003cp\u003eIndex 213\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":53515637195095,"sku":"9781118886014","price":54.86,"currency_code":"GBP","in_stock":true}],"url":"https:\/\/bookcurl.com\/products\/the-ada-practical-guide-to-substance-use-disorders-and-safe-prescribing-9781118886014","provider":"Book Curl","version":"1.0","type":"link"}